NasdaqCM:BSGM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioSig Technologies, Inc., a medical technology company, engages in developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has BioSig Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BSGM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

14.7%

BSGM

-5.6%

US Medical Equipment

2.4%

US Market


1 Year Return

74.5%

BSGM

13.1%

US Medical Equipment

9.2%

US Market

Return vs Industry: BSGM exceeded the US Medical Equipment industry which returned 13.1% over the past year.

Return vs Market: BSGM exceeded the US Market which returned 9.2% over the past year.


Shareholder returns

BSGMIndustryMarket
7 Day14.7%-5.6%2.4%
30 Day32.8%5.0%10.2%
90 Day214.1%6.8%3.4%
1 Year74.5%74.5%14.0%13.1%11.6%9.2%
3 Year238.5%238.5%59.2%54.9%33.7%24.9%
5 Year64.3%64.3%107.5%86.0%59.7%41.8%

Price Volatility Vs. Market

How volatile is BioSig Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioSig Technologies undervalued compared to its fair value and its price relative to the market?

19.35x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BSGM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BSGM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BSGM is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: BSGM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BSGM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BSGM is overvalued based on its PB Ratio (19.4x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is BioSig Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

27.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioSig Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BioSig Technologies performed over the past 5 years?

-26.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BSGM is currently unprofitable.

Growing Profit Margin: BSGM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BSGM is unprofitable, and losses have increased over the past 5 years at a rate of -26.2% per year.

Accelerating Growth: Unable to compare BSGM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BSGM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.2%).


Return on Equity

High ROE: BSGM has a negative Return on Equity (-257.64%), as it is currently unprofitable.


Next Steps

Financial Health

How is BioSig Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: BSGM's short term assets ($16.6M) exceed its short term liabilities ($1.6M).

Long Term Liabilities: BSGM's short term assets ($16.6M) exceed its long term liabilities ($201.3K).


Debt to Equity History and Analysis

Debt Level: BSGM is debt free.

Reducing Debt: BSGM had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BSGM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BSGM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.4% each year


Next Steps

Dividend

What is BioSig Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BSGM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BSGM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BSGM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BSGM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BSGM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Ken Londoner (51yo)

2.92yrs

Tenure

US$5,034,850

Compensation

Mr. Kenneth L. Londoner, also known as Ken, MBA, founded BioSig Technologies, Inc. in 2009 and has been its Chief Executive Officer since July 2017. Mr. Londoner has been Managing Partner of Endicott Manag ...


CEO Compensation Analysis

Compensation vs Market: Ken's total compensation ($USD5.03M) is above average for companies of similar size in the US market ($USD1.35M).

Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Kenneth Londoner
Founder2.92yrsUS$5.03m4.9% $14.5m
Steven Chaussy
Chief Financial Officer2.42yrsUS$2.07m2.59% $7.7m
Budimir Drakulic
Chief Scientist11.33yrsUS$243.75kno data
Lora Mikolaitis
Vice President of Administrationno dataUS$147.00k0.15% $430.2k
Andrew Ballou
Vice President of Investor Relations0.67yrno datano data
John Kowalski
Vice President of Sales1.33yrsno data0.43% $1.3m
Olivier Chaudoir
Senior Director of Marketing0.92yrno datano data
Natasha Drapeau
Executive Vice President3.08yrsno datano data

2.4yrs

Average Tenure

58yo

Average Age

Experienced Management: BSGM's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kenneth Londoner
Founder2.92yrsUS$5.03m4.9% $14.5m
Donald Foley
Independent Director4.67yrsUS$181.88k0.49% $1.4m
Jeffrey O'Donnell
Lead Independent Director1.42yrsUS$514.46k0.83% $2.5m
Jerome Zeldis
Independent Director1.08yrsUS$169.38k0.41% $1.2m
Kent Williams
Member of Advisory Board2.25yrsno datano data
David Weild
Independent Director5.08yrsUS$214.81k0.076% $226.8k
Andrew Filler
Independent Director2.58yrsUS$226.50k0.38% $1.1m
Sim Farar
Member of Advisory Board2.08yrsno datano data
Patrick Gallagher
Independent Director5.92yrsUS$214.81k0.21% $624.8k
Ramachandra Malya
Member of Advisory Board2.25yrsno datano data

2.4yrs

Average Tenure

62yo

Average Age

Experienced Board: BSGM's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BSGM insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.9%.


Top Shareholders

Company Information

BioSig Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioSig Technologies, Inc.
  • Ticker: BSGM
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$296.599m
  • Shares outstanding: 26.16m
  • Website: https://www.biosig.com

Number of Employees


Location

  • BioSig Technologies, Inc.
  • 54 Wilton Road
  • 2nd Floor
  • Westport
  • Connecticut
  • 6880
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BSGMNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2014

Biography

BioSig Technologies, Inc., a medical technology company, engages in developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. The company’s first product, PURE EPTM System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. The company has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EPTM System in August 2018. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Westport, Connecticut. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/04 04:41
End of Day Share Price2020/06/03 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.